The 'magic' of L-dopa: Why is it the gold standard Parkinson's disease therapy?

Trends in Pharmacological Sciences

Volumn 26, Issue 7, 2005, Pages 341-344

  Mercuri, Nicola Biagio ^a   Bernardi, Giorgio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; LEVODOPA;

ANIMAL BEHAVIOR; CLINICAL PROTOCOL; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STANDARD; TREATMENT OUTCOME;

EID: 20544476874     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.05.002     Document Type: Article

References (40)

1. G. Rao Does this patient have Parkinson disease? J. Am. Med. Assoc. 289 2003 347 353
2. Y. Agid Biochemistry of Parkinson's disease 28 years later: a critical review Mov. Disord. 4 1989 S126 S144
3. M. Ruberg Dopamine denervation, age of onset, and Parkinson's disease Neurology 45 1995 392 393
4. W. Birkmayer, and O. Hornykiewicz The effect of L-3,4- dihydroxyphenylalanine (L-DOPA) on akinesia in Parkinsonism. Wiener Klin Wochenschr; 73 787-788. English translation (1998) Parkinsonism Relat. Disord. 4 1961 59 60
5. E.C. Wolters Preclinical (premotor) Parkinson's disease J. Neurol. 247 Suppl. 2 2000 II103 II109
6. C.D. Marsden, and J.D. Parkes "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy Lancet 1 1976 292 296
7. U.K. Rinne Problems associated with long-term levodopa treatment of Parkinson's disease Acta Neurol. Scand. Suppl. 95 1983 19 26
8. S. Fahn Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 8 1997 376 393
9. S. Fahn, and D.B. Calne Consideration in the management of parkinsonism Neurology 28 1978 5 7
10. S. Fahn Levodopa and the progression of Parkinson's disease. The Parkinson Study Group New Engl. J. Med. 351 2004 2498 2508
11. O. Civelli Molecular diversity of the dopamine receptors Annu. Rev. Pharmacol. Toxicol. 33 1993 281 307
12. I. Aubert Increased D-1 dopamine receptor signalling in levodopa-induced dyskinesia Ann. Neurol. 57 2005 17 26
13. P. Jenner Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease Curr. Opin. Neurol. 16 2003 S3 S7
14. G.C. Cotzias Similarities between neurologic effect of L-dopa and of apomorphine New Engl. J. Med. 282 1970 31 35
15. U.K. Rinne Early dopamine agonist treatment in Parkinson's disease A. Lieberman X. Lataste Parkinson's Disease the Role of Dopamine Agonists 1989 The Partheon Publishing Group 29 UK
16. J.L. Montastruc A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five-year follow up J. Neurol. Neurosurg. Psychiatry 57 1994 1034 1038
17. C.E. Clarke Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease Lancet Neurol. 3 2004 466 474
18. O. Rascol A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa New Engl. J. Med. 342 2000 1484 1491
19. O. Rascol Limitations of current Parkinson's disease therapy Ann. Neurol. 53 2003 S3 S15
20. D.S. Kim Dopamine-deficient mice are hypersensitive to dopamine receptor agonists J. Neurosci. 20 2000 4405 4413
21. S. Robinson Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia Proc. Natl. Acad. Sci. U. S. A. 101 2004 13329 13334
22. A. Lopez Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 2001 639 651
23. B.J. Venton Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing J. Neurochem. 87 2003 1284 1295
24. R.R. Gainetdinov, and M.G. Caron Monoamine transporters: from genes to behavior Annu. Rev. Pharmacol. Toxicol. 43 2002 261 284
25. J.G. Nutt The dopamine transporter: importance in Parkinson's disease Ann. Neurol. 55 2004 766 773
26. P. Piccini Endogenous dopamine release after pharmacological challenges in Parkinson's disease Ann. Neurol. 53 2003 647 653
27. N.B. Mercuri Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease Ann. Neurol. 43 1998 613 617
28. M. Riekkinen Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease Eur. J. Neurosci. 10 1998 1429 1435
29. P. Riederer Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome J. Neural Transm. 41 1977 241 251
30. R. Cools Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET Brain 125 2002 584 594
31. A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther. 303 2002 791 804
32. S.H. Fox Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan Mov. Disord. 16 2001 642 650
33. M.S. Sonders Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants J. Neurosci. 17 1997 960 974
34. N.B. Mercuri Electrophysiological pharmacology of the autoreceptor-mediated responses of dopaminergic cells to antiparkinsonian drugs Trends Pharmacol. Sci. 18 1997 232 235
35. D.J. Edwards Effects of L-DOPA on the excretion of alcoholic metabolites of catecholamines and trace amines in rat and human urine Biochem. Med. 25 1981 135 148
36. R. Geracitano Inhibitory effects of trace amines on rat midbrain dopaminergic neurons Neuropharmacology 46 2004 807 814
37. N. Barroso, and M. Rodriguez Action of beta-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission Eur. J. Pharmacol. 297 1996 195 203
38. M. Federici Dopamine selectively reduces GABA(B) transmission onto dopaminergic neurones by an unconventional presynaptic action J. Physiol. 540 2002 119 128
39. R. de la Fuente-Fernandez Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model Brain 127 2004 888 899
40. P.J. Blanchet Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients Can. J. Neurol. Sci. 23 1996 189 193